Revolution Medicines reiterates $2.1B-$2.2B 2026 GAAP operating expense guidance following RASONQUE launch

• "The third quarter marked a transformational period for Revolution Medicines" as the company said "the FDA approved RASONQUE" on August 26 and it "immediately began making it available by prescription in the United States" (CEO, President & Chairman

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.